Back to top

Analyst Blog

On Sep 11, we retained Abiomed Inc. (ABMD - Analyst Report) at Neutral, following its not-so-impressive first-quarter fiscal 2014 results. Although the company is making significant progress with its flagship Impella products, higher operating as well as legal expenses is pressurizing ABMD’s bottom line.

Why the Retention?

On Aug 1, the leading cardiac assist devices maker’s first-quarter fiscal 2014 adjusted earnings dropped 37.5% to 5 cents per share. It also missed the Zacks Consensus Estimate of 6 cents by 16.7%. However, revenues climbed 10% in the quarter to $42.7 million, which was roughly in line with the Zacks Consensus Estimate.

Following the release of fiscal first quarter results, the Zacks Consensus Estimate for fiscal 2014 plunged 45.5% to 12 cents. However, the same for fiscal 2015 marginally declined by 3.7% to 52 cents.

The company’s engagement in a number of legal issues and various regulatory submissions are increasing expenses, which, in turn, resulted in net loss in the fiscal first quarter. This has also driven management to lower its operating margin guidance for fiscal 2014. However, they are confident that bottom line will stabilize in 2015 on the back of cost saving measures and controlled SG&A and R&D spending.

ABMD is a medical device company with a blue streak growth path. The company enjoys a strong demand for its Impella products. Multiple near-term drivers, including new products and clinical trials, should further boost the use of Impella. The company also has a solid cash position.

Other Stocks to Consider

Currently, ABMD has a Zacks Rank #3 (Hold). However, other medical instrument companies such as Luminex (LMNX - Analyst Report), Given Imaging and Echo Therapeutics (ECTE - Snapshot Report) are worth considering. All these stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%